KEY HIGHLIGHTS
-
LuPIN study enrolling heavily pre-treated men with progressive late-stage prostate cancer (mCRPC)
-
Clinical data shows combining Veyonda with radiopharmaceutical, 177Lu-PSMA-617, is well tolerated and with early signals of anti-cancer activity
-
Overall 69% PSA response rate (>50% reduction in PSA levels) with 177Lu-PSMA-617 + Veyonda
SYDNEY, 26 June, 2019: Noxopharm Ltd (ASX: NOX) (‘Noxopharm’ or the ‘Company’) is pleased to report on positive interim clinical data from the ongoing LuPIN study of its lead drug candidate, Veyonda, presented today at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2019 Annual Meeting, June 22-25, in Anaheim, California.
For further information please download the attached PDF:
Download this document
